摘要
【摘要】 目的 观察重组人Ⅱ型肿瘤坏死因子受体 -抗体融合蛋白（益赛普）治疗类风湿关节炎的疗效。方法 50例类风湿关节炎患者， 随机分成对照组和试验组， 各 25例。对照组采用甲氨喋呤和柳氮磺吡啶结合治疗， 试验组采用甲氨喋呤和益赛普结合治疗。对比两组患者在治疗后第 1、 4、 8周的临床效果。结果 试验组在接受治疗后第 1、 4、 8周各指标有效率 [ACR20（ 36.0%、 60.0%、 88.0%）、 ACR50（ 20.0%、 44.0%、 48.0%）、 ACR70（ 16.0%、 16.0%、 32.0%） ]均高于对照组同时点， 差异均具有统计学意义（ P<0.05）。结论 益赛普对于治疗类风湿关节炎具有很好的临床效果， 值得应用推广。
【关键词】 重组人Ⅱ型肿瘤坏死因子受体 -抗体融合蛋白；类风湿关节炎；临床疗效
[Abstract] Objective To observe the therapeutic effect of recombinant human tumor necrosis factor receptor antibody fusion protein (yisaipu) on rheumatoid arthritis. Methods 50 patients with rheumatoid arthritis were randomly divided into control group and experimental group, 25 cases each. The control group was treated with methotrexate and sulfasalazine, while the experimental group was treated with methotrexate and yisaipu. The clinical effects of the two groups were compared in the first, fourth and eighth weeks after treatment. Results in the first, fourth and eighth weeks after treatment, the effective rate of each index in the experimental group [ACR20 (36.0%, 60.0%, 88.0%), acr50 (20.0%, 44.0%, 48.0%), acr70 (16.0%, 16.0%, 32.0%)] was higher than that in the control group at the same time, and the difference was statistically significant (P < 0.05). Conclusion yisaipu has a good clinical effect in the treatment of rheumatoid arthritis, and it is worth popularizing.
出版日期
2020年04月08日（中国期刊网平台首次上网日期，不代表论文的发表时间）
